Parkinson Disease and the pharmacological importance of Leucine‐Rich Repeat Kinase 2 (LRRK2)

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorAbu Dayyeh, Ahmad Mahmoud
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-08-17T08:25:08Z
dc.date.available2022-08-17T08:25:08Z
dc.date.created2022-05-05
dc.description.abstractLRRK2 inhibitors have been produced in several generations, with each iteration improving in potency, selectivity, and brain penetrability. LRRK2 inhibitors may thus be employed in clinical practice for Parkinson's disease therapy in the future. However, their efficacy and safety are still issues that must be solved before they may be used. More study is needed to understand the activities of LRRK2 and broaden its applicability in Parkinson's disease treatment, and even if LRRK2 inhibitors show helpful and safe, the time at which LRRK2 inhibition should be started remains unknown. It is uncertain if inhibiting LRRK2 can prevent or reverse the loss of DA neurons in the midbrain.hu_HU
dc.description.correctorLB
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent39hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/336528
dc.language.isoenhu_HU
dc.subjectParkinsonhu_HU
dc.subject.dspaceDEENK Témalista::Medicinehu_HU
dc.titleParkinson Disease and the pharmacological importance of Leucine‐Rich Repeat Kinase 2 (LRRK2)hu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)